These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1191 related items for PubMed ID: 18025884

  • 1. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
    McComsey GA, Kendall MA, Tebas P, Swindells S, Hogg E, Alston-Smith B, Suckow C, Gopalakrishnan G, Benson C, Wohl DA.
    AIDS; 2007 Nov 30; 21(18):2473-82. PubMed ID: 18025884
    [Abstract] [Full Text] [Related]

  • 2. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
    Bonnick S, Broy S, Kaiser F, Teutsch C, Rosenberg E, DeLucca P, Melton M.
    Curr Med Res Opin; 2007 Jun 30; 23(6):1341-9. PubMed ID: 17594775
    [Abstract] [Full Text] [Related]

  • 3. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pizzonia M, Palummeri E, Bianchi G.
    J Am Geriatr Soc; 2007 May 30; 55(5):752-7. PubMed ID: 17493196
    [Abstract] [Full Text] [Related]

  • 4. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
    Stoch SA, Saag KG, Greenwald M, Sebba AI, Cohen S, Verbruggen N, Giezek H, West J, Schnitzer TJ.
    J Rheumatol; 2009 Aug 30; 36(8):1705-14. PubMed ID: 19487264
    [Abstract] [Full Text] [Related]

  • 5. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
    Giusti A, Barone A, Pioli G, Girasole G, Siccardi V, Palummeri E, Bianchi G.
    Nephrol Dial Transplant; 2009 May 30; 24(5):1472-7. PubMed ID: 19075192
    [Abstract] [Full Text] [Related]

  • 6. Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study.
    Tee SI, Yosipovitch G, Chan YC, Chua SH, Koh ET, Chan YH, Tan SS, Tsou IY, Tan SH.
    Arch Dermatol; 2012 Mar 30; 148(3):307-14. PubMed ID: 22105813
    [Abstract] [Full Text] [Related]

  • 7. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul 30; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

  • 8. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
    Skordis N, Ioannou YS, Kyriakou A, Savva SC, Efstathiou E, Savvides I, Christou S.
    Pediatr Endocrinol Rev; 2008 Oct 30; 6 Suppl 1():144-8. PubMed ID: 19337169
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R.
    Bone; 2006 Dec 30; 39(6):1268-75. PubMed ID: 16884968
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
    Planas J, Trilla E, Raventós C, Cecchini L, Orsola A, Salvador C, Placer J, Encabo G, Morote J.
    BJU Int; 2009 Dec 30; 104(11):1637-40. PubMed ID: 19549260
    [Abstract] [Full Text] [Related]

  • 13. Alendronate for steroid-induced osteopenia in children with acute lymphoblastic leukaemia or non-Hodgkin's lymphoma: results of a pilot study.
    Wiernikowski JT, Barr RD, Webber C, Guo CY, Wright M, Atkinson SA.
    J Oncol Pharm Pract; 2005 Jun 30; 11(2):51-6. PubMed ID: 16460605
    [Abstract] [Full Text] [Related]

  • 14. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection.
    Mondy K, Powderly WG, Claxton SA, Yarasheski KH, Royal M, Stoneman JS, Hoffmann ME, Tebas P.
    J Acquir Immune Defic Syndr; 2005 Apr 01; 38(4):426-31. PubMed ID: 15764959
    [Abstract] [Full Text] [Related]

  • 15. [The efficacy of alendronate in the prevention and treatment of postmenopausal osteoporosis].
    Cheng ZQ, Yin W, Fan JY, Ma TJ.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2002 Jun 01; 24(3):306-9. PubMed ID: 12905641
    [Abstract] [Full Text] [Related]

  • 16. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study.
    Millonig G, Graziadei IW, Eichler D, Pfeiffer KP, Finkenstedt G, Muehllechner P, Koenigsrainer A, Margreiter R, Vogel W.
    Liver Transpl; 2005 Aug 01; 11(8):960-6. PubMed ID: 16035083
    [Abstract] [Full Text] [Related]

  • 17. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
    Biermasz NR, Hamdy NA, Pereira AM, Romijn JA, Roelfsema F.
    Clin Endocrinol (Oxf); 2004 May 01; 60(5):568-75. PubMed ID: 15104559
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK, Chadha M, Modi KD, Kumar KM, Mehrotra R, Sriram U.
    J Assoc Physicians India; 2008 Jun 01; 56():418-24. PubMed ID: 18822620
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
    Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS.
    J Bone Miner Res; 2010 Oct 01; 25(10):2239-50. PubMed ID: 20499357
    [Abstract] [Full Text] [Related]

  • 20. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.
    Choi HJ, Im JA, Kim SH.
    Maturitas; 2008 Jun 20; 60(2):170-6. PubMed ID: 18572334
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 60.